| Company* (Country; Symbol) | Company | Type/Product Area | Terms/Details (Date) |
| Cepheid (CPHD) | Northrup Grumman | Five-year master purchase agreement for up to $200M in Bacillus anthracis (anthrax) test cartridges and associated materials | The anthrax test is currently used in bio-hazard detection systems installed at U.S. Postal Service mail processing centers nationwide (8/16) |
| Chembio Diagnostics Inc. (OTC BB: CEMI) | Pall Corp. | Collaboration in a deal that will use chembio's new Dual Path Platform | The initial collaboration will focus on the feasibility of one application of the tech- nology; Pall will fund feasibility studies, which could lead to license and other agreements (7/31) |
| DNAPrint Genomics Inc. (OTC BB:DNAG) | Dutchess Private Equities Fund Ltd. | Agreement under which $6M in notes and incentive debentures may be paid in full by the issuance of stock and warrants in connection with a proposed spin-off of DNAPrint's wholly-owned subsidiary, DNAPrint Pharmaceuticals Inc. | Following the spin-off, the subsidiary would issue up to 2M shares of common stock to Dutchess as payment for amounts due under certain notes that were made by DNAPrint; Dutchess would be entitled to significant royalty income from the subsidiary and 4% of all DNAPrint sales, which would be credited toward retirement of the debt (7/31) |
| Panagene Inc.* | Copenhagen Inventor Group | Licensing agreement to sell PNA monomers | Panagene will synthesize, manufacture and sell peptide nucleic acids monomers for use by researchers (7/3) |
| ProMetic Life Sciences Inc. (Canada; TSX:PLI) | A European plasma fractionator | Development contract for 12 months to use prion-binding ligands to minimize the risk of transmission by plasma-derived products | Contract is worth $1.7M (7/3) |
| Protein Polymer Technologies Inc. (OTC BB:PPTI) | Unnamed medical device company | Agreement to provide genetically engineered protein polymer biomaterials for use in drug discovery applications | Terms of the deal were not disclosed (7/9) |
| Senomyx Inc. (SNMX) | Kraft Foods Global Inc. | Extended a discovery and development collaboration through December 2008 | Kraft Foods will continue evaluation of flavor modifiers under development by Senomyx in the dessert and powdered beverage categories (7/19) |
| Notes: | |||
| * Private companies are indicated with an asterisk. | |||
| Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
| OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | |||
To read more on related topics, click on one of the words below.